Pancreatic cancer treatment has seen a significant advancement with Rasonque, a drug analyzed by Dr. Monique Yohanan from Revolution Medicines. A clinical trial showed that patients with stage 4 pancreatic cancer experienced a median survival of 13.2 months with Rasonque, compared to 6.7 months with standard chemotherapy. This is particularly encouraging for a disease with a historical stage 4 survival rate of three percent.
An experimental medication, when used alongside standard chemotherapy, showed promise in shrinking tumors or halting their growth in patients with advanced pancreatic cancer. This outcome was presented at the EORTC-NCI-AACR Symposium in Barcelona.
The study was a phase 1/2 trial involving a daily oral pill, daraxonrasib, and two standard chemotherapy drugs: gemcitabine and nab-paclitaxel. The trial included 61 patients with metastatic pancreatic cancer who had not undergone prior treatment. These patients usually face a five to six-month period before the disease becomes aggressive again, and survival typically ranges from eight to 11 months with only chemotherapy.
By integrating daraxonrasib with chemotherapy, tumors shrank or stopped growing in 90.2 percent of untreated, advanced pancreatic cancer cases. Data from the National Cancer Institute indicates that a mere three percent of patients with distant-stage pancreatic cancer survive five years beyond diagnosis.
The study, which had a median follow-up of 18 months, reported a tumor reduction in 60.7 percent of participants, with 8.2 percent achieving complete disappearance of tumors in scans. The treatment prevented tumor growth in 90.2 percent of cases.
Patients experienced a median duration of 12.8 months before cancer progression, nearly double the standard chemotherapy duration. Study lead Dr. Wungki Park highlighted substantial tumor shrinkages and extended disease control, with median progression-free survival exceeding one year.
Most side effects, such as rash, diarrhea, fatigue, and low blood cell counts, were managed with standard care. Only five percent stopped treatment due to daraxonrasib-related side effects.
Daraxonrasib targets the RAS gene, responsible for driving over 90 percent of pancreatic cancers. It aims to inhibit the gene’s ability to promote tumor growth, which was once deemed nearly impossible to achieve with medication.
Dr. Elena Garralda, not involved in the study but a chair of the symposium, remarked on the potential for RAS-targeted drugs to offer more enduring treatment advantages when combined with existing protocols.
This trial notes limitations being an early-phase, single-group study. Without a direct comparison group receiving only standard chemotherapy, it remains unclear exactly how much better this new method is. A more comprehensive randomized phase 3 trial is underway to provide further clarity and verify the benefits of daraxonrasib in a broader context.
Funding for the trial was provided by Revolution Medicines. Current trials are examining the drug’s applicability across other cancers involving RAS mutations, such as in lung and colorectal cancers.
